Semaglutide Combination Investigated for Interaction with Oral Contraceptives

Type 2 diabetes (T2D) is a chronic metabolic disorder requiring effective treatments, with semaglutide being a prominent GLP-1 receptor agonist. Novo Nordisk is developing a novel combination therapy of semaglutide with the investigational drug NNC0480-0389 to further improve blood sugar control. However, the potential for this new combination therapy to interact with the pharmacokinetics (how the body handles a drug) of commonly used oral medications, specifically oral contraceptives, was unknown.

The study systematically evaluated the pharmacokinetic parameters of ethinylestradiol and levonorgestrel when co-administered with semaglutide and NNC0480-0389. Key measurements included the AUC (area under the plasma concentration-time curve) and Cmax (maximum plasma concentration) for both contraceptive components. The investigation involved 27 healthy postmenopausal females. The primary finding was the assessment of whether the novel semaglutide and NNC0480-0389 combination therapy significantly altered the systemic exposure of ethinylestradiol and levonorgestrel. While specific quantitative results are not detailed in the summary, the study's completion indicates that data on these interactions were collected and analyzed. This data would inform whether dose adjustments for oral contraceptives might be necessary if co-prescribed with the new combination therapy.